Search Results

Avirmax Inc., will make two scientific presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) annual meeting in Baltimore between May 7th and 11th, 2024.

Avirmax Biopharma Inc., will make three scientific presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle between May 5th and 9th, 2024.

Avirmax Biopharma, Inc. is pleased to announce that it has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase I/IIa clinical trial for its gene therapy treatment targeting wet Age-related Macular Degeneration.

Avirmax Inc., Vice President of Research, Dr. Li Ou, and Associate Director of Operations, Ms. June Song , will attend the BioProcess International meeting in Boston between September 18th to 21st , 2023.

Avirmax Biopharma Inc. (ABI), Chief Executive and Scientific Officer, Shengjiang Shawn Liu will present the Avirmax BioPharma Inc (ABI)'s progress in the innovation and development of genetic medicines for glaucoma treatment at Glaucoma 360 New Horizons Forum at The Westin St. Francis in San Francisco, Feb 03, 2023.

Avirmax Biopharma Inc. (ABI), Chief Executive and Scientific Officer, Shengjiang Shawn Liu will present results of a three-year study that systematically compared the recombinant adeno-associated virus (rAAV) vector products manufactured using insect Sf9 and human HEK293 cell culture systems at the 26th ASGCT annual conference in Los Angeles, at 2:30 pm. of May 18.

Avirmax CMC Inc. (ACI), a global leader in recombinant adeno associated vector (rAAV) bioprocess development and manufacturing, using a recombinant baculovirus Sf9 cell (rBV-Sf9-AAV) system, has manufactured, tested and released its first batch of rAAV product for use in monkey toxicology and pharmacology studies for an ocular indication.